{"organizations": [], "uuid": "b8125625e11086d0cffcb2124e5d3ed31ffaf267", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/10", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/01/globe-newswire-vbl-therapeutics-to-report-first-quarter-2018-financial-results-on-may-17.html", "country": "US", "domain_rank": 767, "title": "VBL Therapeutics to Report First Quarter 2018 Financial Results on May 17", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T16:00:00.000+03:00", "replies_count": 0, "uuid": "b8125625e11086d0cffcb2124e5d3ed31ffaf267"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/01/globe-newswire-vbl-therapeutics-to-report-first-quarter-2018-financial-results-on-may-17.html", "ord_in_thread": 0, "title": "VBL Therapeutics to Report First Quarter 2018 Financial Results on May 17", "locations": [], "entities": {"persons": [], "locations": [{"name": "israel", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "vbl therapeutics", "sentiment": "negative"}, {"name": "vbl vascular biogenics ltd.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "TEL AVIV, Israel, May 01, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, May 17 at 8:30am Eastern Time to report first quarter ended March 31, 2018 financial results.\nThursday, May 17th @ 8:30am Eastern Time\nUS Domestic: 877-222-6394\nInternational: 1-703-925-2702\nConference ID: 9993639\nWebcast: https://edge.media-server.com/m6/p/zja7xger\nReplays, Available through May 31, 2018\nUS Domestic: 855-859-2056\nInternational: 1-404-537-3406\nConference ID: 9993639\nAbout VBL\nVascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.\nINVESTOR CONTACT:\nMichael Rice\nLifeSci Advisors, LLC\n(646) 597-6979\nSource: VBL Therapeutics", "external_links": ["https://www.globenewswire.com/Tracker?data=v0mMUQgGaLsMpOKt0DKKpIKFQR0NLIxZE2JDX739gUd5D0xwWIcxsfC6JaF6zMId-iY0MBiZW6OZcDSkFmnTUIn9-81viCXQsTWOqT7g-95uppAhItT5O_a6yYd_I7BsMh5sLMD_Bg_EwYDvnFvvNA==", "https://edge.media-server.com/m6/p/zja7xger", "https://www.globenewswire.com/NewsRoom/AttachmentNg/9bc3b19f-b748-4a4f-b77f-a9625602f9e4"], "published": "2018-05-01T16:00:00.000+03:00", "crawled": "2018-05-01T19:00:11.000+03:00", "highlightTitle": ""}